Revvity (RVTY) Q4 2025 earnings review
Strong Q4 Finish, But Margins Compress and 2026 Outlook is Cautious
Revvity ended FY25 with momentum, delivering 4% organic revenue growth in Q4—a notable acceleration from the 1% seen in Q3. This beat was driven entirely by the Diagnostics segment (+7% organic), while Life Sciences remained flat. Despite the top-line beat, profitability quality deteriorated: Adjusted Operating Margin contracted 60bps YoY to 29.7%, with declines in both segments. Management initiated FY26 guidance projecting modest 2-3% organic growth and Adjusted EPS of $5.35-$5.45, implying high-single-digit earnings growth despite the conservative top-line view.
🐂 Bull Case
Diagnostics was the standout hero of Q4, accelerating to 7% organic growth (up from 2% in Q3). This suggests the non-China portion of the portfolio is performing exceptionally well, offsetting the known DRG headwinds in the region.
Revvity deployed capital aggressively in FY25, repurchasing over $820M in stock (reducing share count to ~113M vs ~122M prior year). With leverage managed (net debt/EBITDA ~2.6x previously reported), the company retains firepower.
🐻 Bear Case
Profitability weakened despite higher volumes. Adjusted Operating Margin fell to 29.7% (vs 30.3% YoY). More concerning is the ubiquity of the decline: Life Sciences margins fell 130bps and Diagnostics margins fell 230bps YoY.
The Life Sciences segment reported 0% organic growth in Q4. Given this segment houses the high-growth Signals Software business (historically +20-30%), this implies significant weakness in the underlying instrument/reagent business or a sudden deceleration in software.
⚖️ Verdict: ⚪
Neutral. The revenue acceleration in Q4 is encouraging, particularly in Diagnostics, but the margin deterioration across both segments prevents a higher grade. The FY26 outlook (2-3% organic growth) suggests management does not anticipate a rapid snap-back in Life Sciences demand or China recovery.
Key Themes
Diagnostics Margin Erosion
While Diagnostics revenue surged (+7% organic), the segment's adjusted operating margin collapsed by 230 basis points YoY to 23.4%. This indicates that the growth is coming from lower-margin mix or that the China DRG (Diagnosis-Related Group) pricing pressure is hitting profitability harder than top-line volumes.
China Headwinds Persist
The China immunodiagnostics business continues to face headwinds from DRG implementation. While Q4 revenue acceleration suggests the *rest* of the business is compensating, the margin compression hints that China profitability remains impaired. Management previously noted this headwind would persist until mid-2026 anniversary.
Life Sciences Organic Stagnation
Life Sciences posted 0% organic growth in Q4. This is a deceleration from Q2 (+4%) and suggests the 'recovery' in pharma/biotech spending remains elusive. If Signals Software grew at its historical double-digit rate, the core instrument/reagent business likely contracted materially.
Aggressive Share Repurchases
Management continues to view their own stock as the best ROI. FY25 saw $820M in buybacks, significantly aiding the EPS growth ($5.06 FY25 vs $4.90 FY24) despite flat/low-growth revenue.
Other KPIs
Accelerating. Up 20% YoY from $1.42 in 24Q4. This outpaced revenue growth (+6%) significantly, driven by share count reduction (down ~7% YoY) rather than operational leverage, as operating margins actually contracted.
Decelerating. FY25 Operating Cash Flow ($583M) minus CapEx ($74M) implies ~$509M FCF. This is down from ~$578M in FY24, reflecting working capital timing or lower cash earnings quality.
Reversing. Down from 36.9% in 24Q4. Despite flat organic revenue, the company could not hold margins flat, suggesting negative mix shift (potentially less high-margin software or pricing pressure).
Guidance
Stable. Implies ~4-5% reported growth vs FY25 ($2.86B). This aligns with the 'prudent' stance management has taken throughout 2025.
Decelerating/Stable. The midpoint (2.5%) is slightly below the FY25 actual organic growth of 3%. This suggests management does not expect a V-shaped recovery in 2026.
Accelerating. Implies ~6-8% growth YoY from $5.06 in FY25. This growth rate exceeds the organic revenue guide, indicating reliance on further share buybacks or cost actions to drive the bottom line.
Key Questions
Life Sciences Stagnation vs. Software Strength
With Life Sciences organic growth at 0% in Q4, and assuming Signals Software continued its double-digit growth, does this imply a high-single-digit contraction in the core instrument/reagent portfolio? When do you expect the instrument side to stabilize?
Diagnostics Margin Compression Drivers
Diagnostics organic growth accelerated to 7%, yet margins compressed 230 basis points. How much of this is solely due to the China DRG mix shift, and are there other pricing pressures emerging in the ex-China business?
Prudence of FY26 Guidance
The FY26 organic growth guide of 2-3% is below the 3% achieved in FY25. Are you assuming a further deterioration in the macro environment, or is this purely a function of the China headwind persisting through H1?
Capital Allocation Priorities
You deployed over $800M into buybacks in FY25. With leverage manageable, should we expect a similar cadence in FY26, or does the M&A pipeline look more attractive now that valuations may have reset?